{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Number of participants with dose reductions due to any reason is presented.","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Number of Participants With Dose Reductions","type":"SECONDARY","unitOfMeasure":"Participants"}